

# Luis Eduardo EcheverrÃ-a

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/375267/publications.pdf>

Version: 2024-02-01

41  
papers

2,508  
citations

394421

19  
h-index

276875

41  
g-index

48  
all docs

48  
docs citations

48  
times ranked

3854  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiovascular Complications of Chagas' Disease. , 2022, , 45-60.		0
2	Longitudinal strain by speckle tracking and echocardiographic parameters as predictors of adverse cardiovascular outcomes in chronic Chagas cardiomyopathy. International Journal of Cardiovascular Imaging, 2022, 38, 1245-1255.	1.5	4
3	Longitudinal Speckle Tracking Strain Abnormalities in Chagas Disease: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 769.	2.4	5
4	Chagasâ€™ cardiomyopathy and Lyme carditis: Lessons learned from two infectious diseases affecting the heart. Trends in Cardiovascular Medicine, 2021, 31, 233-239.	4.9	11
5	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. New England Journal of Medicine, 2021, 384, 105-116.	27.0	381
6	Survival after heart transplantation for Chagas cardiomyopathy using a conventional protocol: A 10â€­year experience in a single center. Transplant Infectious Disease, 2021, 23, e13549.	1.7	4
7	COVID-19 in Health-Care Workers: A Living Systematic Review and Meta-Analysis of Prevalence, Risk Factors, Clinical Characteristics, and Outcomes. American Journal of Epidemiology, 2021, 190, 161-175.	3.4	518
8	Chagas Disease: Chronic Chagas Cardiomyopathy. Current Problems in Cardiology, 2021, 46, 100507.	2.4	59
9	Coagulation disorders in Chagas disease: A pathophysiological systematic review and meta-analysis. Thrombosis Research, 2021, 201, 73-83.	1.7	10
10	Admixture mapping analysis reveals differential genetic ancestry associated with Chagas disease susceptibility in the Colombian population. Human Molecular Genetics, 2021, 30, 2503-2512.	2.9	5
11	New treatment regimens for Chagas disease: light at the end of the tunnel?. Lancet Infectious Diseases, The, 2021, 21, 1057-1058.	9.1	2
12	Cardiovascular biomarkers as predictors of adverse outcomes in chronic Chagas cardiomyopathy. PLoS ONE, 2021, 16, e0258622.	2.5	6
13	Cardiovascular Biomarkers and Diastolic Dysfunction in Patients With Chronic Chagas Cardiomyopathy. Frontiers in Cardiovascular Medicine, 2021, 8, 751415.	2.4	1
14	Circulating DHEA-S levels and major cardiovascular outcomes in chronic Chagas cardiomyopathy: A prospective cohort study. International Journal of Cardiology, 2021, , .	1.7	1
15	Roadblocks in Chagas disease care in endemic and nonendemic countries: Argentina, Colombia, Spain, and the United States. The NET-Heart project. PLoS Neglected Tropical Diseases, 2021, 15, e0009954.	3.0	7
16	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: <scp>GALACTICâ€­CHF</scp> baseline characteristics and comparison with contemporary clinical trials. European Journal of Heart Failure, 2020, 22, 2160-2171.	7.1	47
17	Circulating <i>Trypanosoma cruzi</i> load and major cardiovascular outcomes in patients with chronic Chagas cardiomyopathy: a prospective cohort study. Tropical Medicine and International Health, 2020, 25, 1534-1541.	2.3	8
18	Echocardiographic parameters, speckle tracking, and brain natriuretic peptide levels as indicators of progression of indeterminate stage to Chagas cardiomyopathy. Echocardiography, 2020, 37, 429-438.	0.9	9

#	ARTICLE	IF	CITATIONS
19	Efficacy of the Benznidazole+Posaconazole combination therapy in parasitemia reduction: An experimental murine model of acute Chagas. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2020, 53, e20190477.	0.9	7
20	WHF IASC Roadmap on Chagas Disease. <i>Global Heart</i> , 2020, 15, 26.	2.3	75
21	Myocardial Involvement in Chagas Disease and Insulin Resistance: A Non-Metabolic Model of Cardiomyopathy. <i>Global Heart</i> , 2020, 15, 36.	2.3	4
22	COVID-19: Implications for People with Chagas Disease. <i>Global Heart</i> , 2020, 15, 69.	2.3	39
23	Effects of Serelaxin in Patients with Acute Heart Failure. <i>New England Journal of Medicine</i> , 2019, 381, 716-726.	27.0	174
24	American Trypanosomiasis (Chagas Disease). <i>Infectious Disease Clinics of North America</i> , 2019, 33, 119-134.	5.1	145
25	Risk factors for longitudinal changes in left ventricular diastolic function among women and men. <i>Heart</i> , 2019, 105, 1414-1422.	2.9	7
26	Recommendations for Multimodality Cardiac Imaging in Patients with Chagas Disease: A Report from the American Society of Echocardiography in Collaboration With the InterAmerican Association of Echocardiography (ECOSIAC) and the Cardiovascular Imaging Department of the Brazilian Society of Cardiology (DIC-SBC). <i>Journal of the American Society of Echocardiography</i> , 2018, 31, 3-25.	2.8	50
27	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004962.	3.9	117
28	Electrocardiographic abnormalities in Chagas disease in the general population: A systematic review and meta-analysis. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006567.	3.0	53
29	Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2018, 138, e169-e209.	1.6	315
30	Comprehensive analysis of three TYK2 gene variants in the susceptibility to Chagas disease infection and cardiomyopathy. <i>PLoS ONE</i> , 2018, 13, e0190591.	2.5	4
31	Orally transmitted acute Chagas disease in domestic travelers in Colombia. <i>Journal of Infection and Public Health</i> , 2017, 10, 244-246.	4.1	12
32	Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T.ÂCruzi Carriers. <i>Journal of the American College of Cardiology</i> , 2017, 69, 939-947.	2.8	231
33	Extracorporeal Membrane Oxygenation in Dengue, Malaria, and Acute Chagas Disease. <i>ASAIO Journal</i> , 2017, 63, e71-e76.	1.6	5
34	Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	53
35	Profiles of cardiovascular biomarkers according to severity stages of Chagas cardiomyopathy. <i>International Journal of Cardiology</i> , 2017, 227, 577-582.	1.7	24
36	IL18 Gene Variants Influence the Susceptibility to Chagas Disease. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004583.	3.0	24

#	ARTICLE	IF	CITATIONS
37	Determination of Anti-Adeno-Associated Viral Vector Neutralizing Antibodies in Patients With Heart Failure in the Cardiovascular Foundation of Colombia (ANVIAS): Study Protocol. JMIR Research Protocols, 2016, 5, e102.	1.0	6
38	Investigation of the role of IL17A gene variants in Chagas disease. Genes and Immunity, 2015, 16, 536-540.	4.1	22
39	SNP/haplotype associations of CCR2 and CCR5 genes with severity of chagasic cardiomyopathy. Human Immunology, 2014, 75, 1210-1215.	2.4	27
40	Polymorphisms of toll-like receptor 2 and 4 genes in Chagas disease. Memorias Do Instituto Oswaldo Cruz, 2008, 103, 27-30.	1.6	27
41	Validación de constructo de la escala Zung en pacientes con falla cardíaca. Universitas Scientiarum, 0, 23, .	0.2	0